Literature DB >> 17614357

Critical ligand binding reagent preparation/selection: when specificity depends on reagents.

Bonita Rup1, Denise O'Hara.   

Abstract

Throughout the life cycle of biopharmaceutical products, bioanalytical support is provided using ligand binding assays to measure the drug product for pharmacokinetic, pharmacodynamic, and immunogenicity studies. The specificity and selectivity of these ligand binding assays are highly dependent on the ligand binding reagents. Thus the selection, characterization, and management processes for ligand binding reagents are crucial to successful assay development and application. This report describes process considerations for selection and characterization of ligand binding reagents that are integral parts of the different phases of assay development. Changes in expression, purification, modification, and storage of the ligand binding reagents may have a profound effect on the ligand binding assay performance. Thus long-term management of the critical ligand binding assay reagents is addressed including suggested characterization criteria that allow ligand binding reagents to be used in as consistent a manner as possible. Examples of challenges related to the selection, modification, and characterization of ligand binding reagents are included.

Mesh:

Substances:

Year:  2007        PMID: 17614357      PMCID: PMC2751403          DOI: 10.1208/aapsj0902016

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  18 in total

1.  Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.

Authors:  J W Findlay; W C Smith; J W Lee; G D Nordblom; I Das; B S DeSilva; M N Khan; R R Bowsher
Journal:  J Pharm Biomed Anal       Date:  2000-01       Impact factor: 3.935

2.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

3.  Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules.

Authors:  Binodh DeSilva; Wendell Smith; Russell Weiner; Marian Kelley; JoMarie Smolec; Ben Lee; Masood Khan; Richard Tacey; Howard Hill; Abbie Celniker
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

4.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.

Authors:  Anthony R Mire-Sluis; Yu Chen Barrett; Viswanath Devanarayan; Eugene Koren; Hank Liu; Mauricio Maia; Thomas Parish; George Scott; Gopi Shankar; Elizabeth Shores; Steven J Swanson; Gary Taniguchi; Daniel Wierda; Linda A Zuckerman
Journal:  J Immunol Methods       Date:  2004-06       Impact factor: 2.303

Review 5.  Antibodies from phage antibody libraries.

Authors:  Andrew R M Bradbury; James D Marks
Journal:  J Immunol Methods       Date:  2004-07       Impact factor: 2.303

Review 6.  In-vitro protein evolution by ribosome display and mRNA display.

Authors:  Dasa Lipovsek; Andreas Plückthun
Journal:  J Immunol Methods       Date:  2004-07       Impact factor: 2.303

Review 7.  Pharmacokinetic aspects of biotechnology products.

Authors:  Lisa Tang; Adam M Persky; Günther Hochhaus; Bernd Meibohm
Journal:  J Pharm Sci       Date:  2004-09       Impact factor: 3.534

Review 8.  Enzyme immunoassay techniques. An overview.

Authors:  T Porstmann; S T Kiessig
Journal:  J Immunol Methods       Date:  1992-06-24       Impact factor: 2.303

Review 9.  Structure of antibody-antigen complexes: implications for immune recognition.

Authors:  P M Colman
Journal:  Adv Immunol       Date:  1988       Impact factor: 3.543

Review 10.  Aptamers as therapeutic and diagnostic agents.

Authors:  E N Brody; L Gold
Journal:  J Biotechnol       Date:  2000-03       Impact factor: 3.307

View more
  6 in total

Review 1.  Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents.

Authors:  Denise M O'Hara; Valerie Theobald; Adrienne Clements Egan; Joel Usansky; Murli Krishna; Julie TerWee; Mauricio Maia; Frank P Spriggs; John Kenney; Afshin Safavi; Jeannine Keefe
Journal:  AAPS J       Date:  2012-03-14       Impact factor: 4.009

2.  Advances in Bioconjugation.

Authors:  Jeet Kalia; Ronald T Raines
Journal:  Curr Org Chem       Date:  2010-01       Impact factor: 2.180

Review 3.  Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics.

Authors:  Xin Xu; Yulia Vugmeyster
Journal:  AAPS J       Date:  2012-08-04       Impact factor: 4.009

4.  Comparison of succinimidyl [(125)I]iodobenzoate with iodogen iodination methods to study pharmacokinetics and ADME of biotherapeutics.

Authors:  Jianqing Chen; Mengmeng Wang; Alison Joyce; David DeFranco; Mania Kavosi; Xin Xu; Denise M O'Hara
Journal:  Pharm Res       Date:  2014-05-21       Impact factor: 4.200

5.  Recommendations and best practices for reference standards and reagents used in bioanalytical method validation.

Authors:  Joseph F Bower; Jennifer B McClung; Carl Watson; Takahiko Osumi; Kátia Pastre
Journal:  AAPS J       Date:  2014-02-06       Impact factor: 4.009

6.  Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization Team.

Authors:  Lindsay E King; Esme Farley; Mami Imazato; Jeannine Keefe; Masood Khan; Mark Ma; K Susanne Pihl; Priya Sriraman
Journal:  AAPS J       Date:  2014-04-01       Impact factor: 4.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.